Drug Profile
Padnarsertib - Karyopharm Therapeutics
Alternative Names: ATG-019; KPT-9274Latest Information Update: 04 Oct 2023
Price :
$50
*
At a glance
- Originator Karyopharm Therapeutics
- Developer Antengene Corporation; Karyopharm Therapeutics
- Class Amides; Amines; Antineoplastics; Benzofurans; Fluorinated hydrocarbons; Fluorobenzenes; Piperidines; Pyridines; Small molecules
- Mechanism of Action Nicotinamide phosphoribosyltransferase inhibitors; P21 activated kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Acute myeloid leukaemia
- Preclinical Neuroendocrine tumours
- No development reported Non-Hodgkin's lymphoma; Solid tumours
Most Recent Events
- 22 Aug 2023 Karyopharm Therapeutics and University of Colorado re-initiates enrolment in phase-I trial in Acute myeloid leukaemia (Second-line therapy or greater) in USA (PO) (NCT04914845)
- 16 Aug 2023 Karyopharm Therapeutics and University of Colorado suspends a phase-I trial in Acute myeloid leukaemia (Second-line therapy or greater) in USA (PO) due to unknown reasons (NCT04914845)
- 28 May 2023 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma(Combination therapy, Late-stage disease, Second-line therapy or greater) in Taiwan (PO)